Dorothée Faille 🕊🤍

Hôpital Bichat @hopitalbichat - INSERM UMR-S U1144 TEAM 4 🔬💊🧠🩸Diagnostic and therapeutic innovation in cerebrovascular and thrombotic diseases

[Yüksel Ürün @DrYukselUrun]

BREAKING from @NEJM
In cancer patients w/ Cancer-Associated Venous Thromboembolism, reduced-dose apixaban (2.5 mg BID) is :
🔘Noninferior to full-dose (5 mg BID) for VTE recurrence
🔘Lower bleeding risk (12.1% vs. 15.6%)
🔘Safer extended anticoagulation, same protection.
#Thrombosis #cancer @OncoAlert @Cihan_Ay_MD
DOI: 10.1056/NEJMoa2416112

[Dorothée Faille 🕊🤍 @DorotheeFaille]

Order out of Chaos from @NEJM editor-in-chief Eric Rubin https://t.co/OpJE1376YM

[JAMA @JAMA_current]

The risk of venous thromboembolism (VTE) varies across different types of hormonal contraceptives, with the highest risk associated with combined pills containing third-generation progestins.

https://t.co/L2GlFbNm61

[JTH @JTHjournal]

Individuals with a new cancer diagnosis and no stroke history have an increased risk of ischemic stroke which varies according to site and stage. Future research is needed to identify individuals at highest risk who may benefit from preventative treatment
@DebSiegal

🔗https://t.co/cyad3VFAUi

[Marc Carrier @MarcCarrier1]

Cancer-associated thrombosis is not only about venous events. Patients with cancer and no prior strokes have a 1.5 ⬆️risk of ischemic stroke compared to those without cancer. ⬆️risk with certain cancer types
https://t.co/KaBg1DKeP8
@JTHjournal @canvector @ThrombosisCan

[Dorothée Faille 🕊🤍 @DorotheeFaille]

⚠️ Neonatal #VITT-like case
Maternal Anti-PF4 Antibodies as Cause of Neonatal Stroke | @NEJM
#MGTS #PF4 #HIT https://t.co/PlqHrGtMcr

[Ishac Nazy, PhD @IshacNazyPhD]

Our recent study (a global collaboration) @MacDeptMed @Mac_Transfusion @NEJM @MacPlateletLab @BBS_McMasterU @McMasterIIDR @machealthsci
@McMasterU
VITT-like Monoclonal Gammopathy of Thrombotic Significance | New England Journal of Medicine https://t.co/DtvQOehxtY

[Dorothée Faille 🕊🤍 @DorotheeFaille]

Full-text available here : https://t.co/lCEy5FzmHX

[Dorothée Faille 🕊🤍 @DorotheeFaille]

Check out our 🆕️ case report about
Danaparoid failure in #HIT due to acquired antithrombin deficiency
⚠️ AT deficiency lowers danaparoid anti-Xa activity and clinical efficacy
👉 in @ThrombosisRese1
https://t.co/UjAlTu3Sed

[JTH @JTHjournal]

"Can complement activation serve as a reliable functional biomarker to distinguish pathogenic anti-PF4/H antibodies associated with HIT from asymptomatic anti-PF4/H antibodies in patients exposed to heparin?" 🤔

Complement activation offers a new biomarker to identify disease-causing antibodies in Heparin-Induced Thrombocytopenia (HIT). This recent study in JTH journal demonstrates that a simple plasma-based assay can distinguish patients with and without HIT, potentially simplifying diagnostics in clinical settings.

🔗https://t.co/9CFp8rfMjX

[JAMA @JAMA_current]

Based on individual risk factors for thrombosis, persons with essential thrombocythemia may be treated with low-dose aspirin, either alone or in combination with a cytoreductive drug such as hydroxyurea.

https://t.co/Z0jN1ABkPR

[NEJM @NEJM]

Original Article: Continuation versus Interruption of Oral Anticoagulation during TAVI (POPular PAUSE TAVI trial) https://t.co/YUOAyKdsyg

#Cardiology

[NEJM @NEJM]

In patients with atrial fibrillation and moderate-to-high risk of stroke, abelacimab, a monoclonal antibody that inhibits activation of factor XI, led to fewer bleeding events than rivaroxaban. Read the full AZALEA–TIMI 71 trial results: https://t.co/CrHwsbmXMt

#AFib

[NEJM @NEJM]

A new editorial describes the science behind a clinical trial reported by Ruff et al. in which a monoclonal antibody targeting factors XI and XIa was evaluated for its effects on bleeding events in patients with atrial fibrillation. Full editorial: https://t.co/PFU6lOfP7X

[Dorothée Faille 🕊🤍 @DorotheeFaille]

⚠️ **POSTE de PHC temps plein** en Hématologie Biologique & Transfusion 🔬🩸au CHU Louis-Mourier à Colombes (92), orientation cytologie, disponible à partir du 2 mai 2025, évolution possible vers un poste de PH pérenne.
https://t.co/9cKWPUpIHk

[Thrombosis Canada @ThrombosisCan]

À l'occasion de la Journée mondiale de la thrombose, nous vous rappelons notre acronyme VESSO - Vertige (étourdissements), Essoufflement, Serrement à la poitrine, Sensibilité (au mollet) et Oedème de la jambe - pour vous aider à garder à l'esprit les principaux signes et symptômes de la thrombose. Téléchargez ou commandez vos documents CLOTS pour les partager avec vos amis et votre famille. https://t.co/hJA3DcSkAH #CLOTS #KnowThrombose #WTDay24

[Lana Castellucci @LanaCastellucci]

If you are looking for great resources and handouts to share the colleagues, patients, their families, check out @thrombosisday @ThrombosisCan @AnticoagForum @NATFthrombosis @ThrombosisUK @ThrombosisIrL and many, many others!

[World Thrombosis Day @thrombosisday]

📣Know the Signs of DVT!

Thrombosis occurs when a blood clot forms in a vein or artery.

Recognizing these signs early can be crucial in preventing serious complications. Stay informed, #KnowThrombosis and protect your health!

[JTH @JTHjournal]

Today is #WorldThrombosisDay! Thrombosis can affect anyone, anywhere, at any age. Understanding the risks and signs of blood clots is crucial for prevention. Join us in raising awareness and supporting research for better patient outcomes. Together, we can save lives! 🌍
@thrombosisday
#WTday24
#StopTheClot

[Michael Makris @ProfMakris]

Today is #WorldThrombosisDay. You may think thrombosis has nothing to do with you, but you will be wrong. Thrombosis is something everybody will have to address either at a personal or friend/relative level at some stage of their life. #thrombosis #isth #WTDay24